158 related articles for article (PubMed ID: 24256818)
1. Usefulness of plasma YKL-40 in management of community-acquired pneumonia severity in patients.
Wang HL; Hsiao PC; Tsai HT; Yeh CB; Yang SF
Int J Mol Sci; 2013 Nov; 14(11):22817-25. PubMed ID: 24256818
[TBL] [Abstract][Full Text] [Related]
2. Plasma long pentraxin 3 (PTX3) concentration is a novel marker of disease activity in patients with community-acquired pneumonia.
Kao SJ; Yang HW; Tsao SM; Cheng CW; Bien MY; Yu MC; Bai KJ; Yang SF; Chien MH
Clin Chem Lab Med; 2013 Apr; 51(4):907-13. PubMed ID: 23152412
[TBL] [Abstract][Full Text] [Related]
3. Plasma Monocyte Chemoattractant Protein-1 Level as a Predictor of the Severity of Community-Acquired Pneumonia.
Yong KK; Chang JH; Chien MH; Tsao SM; Yu MC; Bai KJ; Tsao TC; Yang SF
Int J Mol Sci; 2016 Jan; 17(2):. PubMed ID: 26840299
[TBL] [Abstract][Full Text] [Related]
4. Circulating level of lipocalin 2 as a predictor of severity in patients with community-acquired pneumonia.
Yeh YH; Chang JL; Hsiao PC; Tsao SM; Lin CH; Kao SJ; Chou MC; Yang SF; Chien MH
J Clin Lab Anal; 2013 Jul; 27(4):253-60. PubMed ID: 23852780
[TBL] [Abstract][Full Text] [Related]
5. Utility of Plasma Osteopontin Levels in Management of Community-Acquired Pneumonia.
Chang JH; Hung WY; Bai KJ; Yang SF; Chien MH
Int J Med Sci; 2016; 13(9):673-9. PubMed ID: 27647996
[TBL] [Abstract][Full Text] [Related]
6. YKL-40, CCL18 and SP-D predict mortality in patients hospitalized with community-acquired pneumonia.
Spoorenberg SM; Vestjens SM; Rijkers GT; Meek B; van Moorsel CH; Grutters JC; Bos WJ;
Respirology; 2017 Apr; 22(3):542-550. PubMed ID: 27782361
[TBL] [Abstract][Full Text] [Related]
7. Significant elevation of plasma cathepsin B and cystatin C in patients with community-acquired pneumonia.
Lee YT; Chen SC; Shyu LY; Lee MC; Wu TC; Tsao SM; Yang SF
Clin Chim Acta; 2012 Mar; 413(5-6):630-5. PubMed ID: 22209964
[TBL] [Abstract][Full Text] [Related]
8. Plasma endothelial cell-specific molecule-1 (ESM-1) in management of community-acquired pneumonia.
Kao SJ; Chuang CY; Tang CH; Lin CH; Bien MY; Yu MC; Bai KJ; Yang SF; Chien MH
Clin Chem Lab Med; 2014 Mar; 52(3):445-51. PubMed ID: 24108208
[TBL] [Abstract][Full Text] [Related]
9. Course of SP-D, YKL-40, CCL18 and CA 15-3 in adult patients hospitalised with community-acquired pneumonia and their association with disease severity and aetiology: A post-hoc analysis.
Spoorenberg SMC; Vestjens SMT; Voorn GP; van Moorsel CHM; Meek B; Zanen P; Rijkers GT; Bos WJW; Grutters JC;
PLoS One; 2018; 13(1):e0190575. PubMed ID: 29324810
[TBL] [Abstract][Full Text] [Related]
10. Elevated plasma stromal-cell-derived factor-1 protein levels correlate with severity in patients with community-acquired pneumonia.
Tsai PK; Hsieh MJ; Wang HL; Chou MC; Yang SF; Yeh CB
Dis Markers; 2014; 2014():829706. PubMed ID: 25371597
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of soluble Axl correlate with severity of community-acquired pneumonia.
Ko CP; Yu YL; Hsiao PC; Yang SF; Yeh CB
Mol Med Rep; 2014 Apr; 9(4):1400-4. PubMed ID: 24503651
[TBL] [Abstract][Full Text] [Related]
12. The circulating level of MMP-9 and its ratio to TIMP-1 as a predictor of severity in patients with community-acquired pneumonia.
Chiang TY; Yu YL; Lin CW; Tsao SM; Yang SF; Yeh CB
Clin Chim Acta; 2013 Sep; 424():261-6. PubMed ID: 23792071
[TBL] [Abstract][Full Text] [Related]
13. CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS.
Richards G; Levy H; Laterre PF; Feldman C; Woodward B; Bates BM; Qualy RL
J Intensive Care Med; 2011; 26(1):34-40. PubMed ID: 21341394
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of plasma neutrophil gelatinase-associated lipocalin concentration for predicting the severity and mortality of patients with community-acquired pneumonia.
Kim JW; Hong DY; Lee KR; Kim SY; Baek KJ; Park SO
Clin Chim Acta; 2016 Nov; 462():140-145. PubMed ID: 27662812
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of soluble intercellular adhesion molecule-1 as a biomarker for disease severity of patients with community-acquired pneumonia.
Chang PY; Tsao SM; Chang JH; Chien MH; Hung WY; Huang YW; Yang SF
Clin Chim Acta; 2016 Dec; 463():174-180. PubMed ID: 27983998
[TBL] [Abstract][Full Text] [Related]
16. Plasma transforming growth factor-beta1 level in patients with severe community-acquired pneumonia and association with disease severity.
Wu HP; Chen CK; Chung K; Jiang BY; Yu TJ; Chuang DY
J Formos Med Assoc; 2009 Jan; 108(1):20-7. PubMed ID: 19181604
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of plasma human β-defensin 2 level on short-term clinical outcomes in patients with community-acquired pneumonia: a preliminary study.
Liu S; He LR; Wang W; Wang GH; He ZY
Respir Care; 2013 Apr; 58(4):655-61. PubMed ID: 23051183
[TBL] [Abstract][Full Text] [Related]
18. The relationship between serum YKL-40 levels and severity of asthma.
Duru S; Yüce G; Ulasli SS; Erdem M; Kizilgün M; Kara F; Ardıc S
Iran J Allergy Asthma Immunol; 2013 Jul; 12(3):247-53. PubMed ID: 23893808
[TBL] [Abstract][Full Text] [Related]
19. Significant association of elevated concentration of plasma YKL-40 with disease severity in patients with pelvic inflammatory disease.
Lee SH; Lin CY; Wang PH; Han CP; Yang SF; Chang JT; Lee MC; Lin LY; Lee MS
J Clin Lab Anal; 2012 May; 26(3):136-42. PubMed ID: 22628227
[TBL] [Abstract][Full Text] [Related]
20. Mortality prediction in community-acquired pneumonia requiring mechanical ventilation; values of pneumonia and intensive care unit severity scores.
Aydoğdu M; Ozyilmaz E; Aksoy H; Gürsel G; Ekim N
Tuberk Toraks; 2010; 58(1):25-34. PubMed ID: 20517726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
